This study is looking at how safe and effective donor bone marrow derived mesenchymal stem cells are for people with heart failure. This heart failure is caused by a type of chemotherapy called anthracyclines, which can damage the heart. Researchers want to see if these stem cells, given either through a vein (intravenously) or directly into the heart muscle (transendocardially), can help control heart failure symptoms and improve heart function. You might be able to join if you are between 18 and 80 years old, have reduced heart pumping ability (left ventricular ejection fraction or LVEF of 40% or less), and heart failure symptoms (NYHA class I, II, or III) due to anthracycline treatment. The study aims to enroll 72 participants and is currently unclear on its recruitment status.

Study design

This is a randomized pilot study, meaning participants are assigned by chance to one of three groups. It aims to enroll 72 participants.

What's involved

Participants will receive either mesenchymal stem cells intravenously, mesenchymal stem cells directly into the heart, or standard heart failure care. The intravenous stem cells are given on four specific days within a month.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed up periodically after their study treatment, with safety and heart function measured up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.